Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Bosulif
(United States) [Available]Synonyms :
bosutinib
Class :
Antineoplastics and Tyrosine Kinase Inhibitor 
Brand Name :
Bosulif
(United States) [Available]Synonyms :
bosutinib
Class :
Antineoplastics and Tyrosine Kinase Inhibitor 
Dosage forms and strength Â
Tablet Â
400 mg Â
Chronic Myelogenous Leukemia (CML)
Take a dose of 400 mg orally once daily:
Chronic Myelogenous Leukemia (CML)
Refer adult dosing
when both drugs are combined, there may be a decrease in the serum concentration of bosutinib
it may decrease the serum concentration of bosutinib
it may decrease the serum concentration of bosutinib
it may decrease the serum concentration of bosutinib
it may decrease the serum concentration of bosutinib
it may decrease the serum concentration of bosutinib
it may decrease the serum concentration of bosutinib
it may decrease the serum concentration of bosutinib
bosutinib: they may diminish the serum concentration of antacids
bosutinib: they may diminish the serum concentration of antacids
bosutinib: they may diminish the serum concentration of antacids
bosutinib: they may diminish the serum concentration of antacids
bosutinib: they may diminish the serum concentration of antacids
bosutinib: they may diminish the serum concentration of antacids
bosutinib: they may diminish the serum concentration of antacids
when both drugs are combined, there may be an increased level of bosutinib by p-glycoprotein (mdr1) efflux transporter  
may diminish the serum concentration when combined
when both drugs are combined, there may be a diminishing of the therapeutic effect of bcg (intravesical)
when both drugs are combined, there may be an increase in the myelosuppressive effect
it may decrease the serum concentration of bosutinib
it may increase the serum concentration of bosutinib
It may diminish the effect when combined with phenobarbital by affecting the intestinal/hepatic enzyme CYP3A4
It may enhance the effect when combined with grapefruit by CYP3A4 metabolism
bosutinib: they may diminish the serum concentration of CYP3A4 Inducers
bosutinib: they may diminish the serum concentration of CYP3A4 Inducers
bosutinib: they may diminish the serum concentration of CYP3A4 Inducers
bosutinib: they may diminish the serum concentration of CYP3A4 Inducers
bosutinib: they may diminish the serum concentration of CYP3A4 Inducers
may enhance the concentration of serum when combined with bosutinib
may enhance the concentration of serum when combined with bosutinib
may enhance the concentration of serum when combined with bosutinib
may enhance the concentration of serum when combined with bosutinib
may enhance the concentration of serum when combined with bosutinib
bosutinib: they may enhance the serum concentration of CYP3A Inhibitors
bosutinib: they may enhance the serum concentration of CYP3A Inhibitors
bosutinib: they may enhance the serum concentration of CYP3A Inhibitors
bosutinib: they may enhance the serum concentration of CYP3A Inhibitors
bosutinib: they may enhance the serum concentration of CYP3A Inhibitors
nafcillin will decrease the effect of action of bosutinib by affecting enzyme CYP3A4 metabolism.
the effect of bosutinib is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
when both drugs are combined, there may be an increased effect of bosutinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
lapatinib increases the effect of bosutinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
CYP3A strong enhancers of the small intestine may reduce the bioavailability of bosutinib
CYP3A4 inducers decrease the concentration of bosutinib in serum
CYP3A4 inhibitors increase the concentration of bosutinib in serum
metronidazole enhances the effect of bosutinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
when both drugs are combined, there may be an increased risk of adverse effects
may enhance the serum concentration of CYP3A4 inhibitors
aminosalicylic acid derivatives
it may increase the myelosuppressive effect
when both drugs are combined, there may be an increase in the serum concentration of cyp3a4 substrates
qt-prolonging agents:   it may increase the qtc-prolonging effect of haloperidol
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
bosutinib together with cisapride lead to an elevation of the QTc interval
Combining tegafur with bosutinib can reduce tegafur’s metabolism
When alprazolam and bosutinib is used together, this leads to reduction in the alprazolam’s metabolism
When domeperidone and bosutinib is used together, this leads to reduction in the domeperidone’s metabolism
The potential for bleeding risk or its seriousness may elevate when bosutinib is used together with troxerutin
When bosutinib is used together with capsaicin, this leads to enhanced risk or seriousness of methemoglobinemia
When bosutinib is used together with andrographolide, this leads to enhanced risk or seriousness of bleeding
When bosutinib is used together with oleandomycin, this leads to enhanced concentration serum of bosutinib
When bosutinib is used together with patupilone, this leads to enhanced concentration serum of bosutinib
When bosutinib is used together with ridaforolimus, this leads to enhanced concentration serum of bosutinib
bosutinib's absorption may be reduced by almasilate, resulting in lower serum concentrations and potentially decreased efficacy
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
QTc interval is increased both by lenvatinib and bosutinib
increases the serum concentration of cabazitaxel by MDR1 efflux transporter
May increase serum level and toxic effects of docetaxel by affecting MDR1/PG-P efflux transporter
when both drugs are combined, there may be an increased QTC interval 
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
relugolix/​estradiol/​norethindroneÂ
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the risk or severity of toxic effects when combined
may decrease the serum concentration of CYP3A4 Inducers
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
the serum levels of bosutinib may be increased
the risk of adverse effects may be increased
Actions and spectrum:Â Â
Bosutinib inhibits the activity of the enzyme tyrosine kinase. It also exerts its action by inhibiting kinases of family SRc.Â
Frequency defined   Â
>10%     Â
All grades   Â
Creatinine increased Â
Hemoglobin decreased Â
Lymphocyte count decreased   Â
Lipase increased   Â
Platelet count decreased   Â
Glucose increased Â
Calcium decreased   Â
Rash Â
Abdominal pain Â
Nausea Â
Headache Â
Vomiting Â
Black Box Warning  Â
None Â
Contraindication/Caution:Â Â
Contraindication:Â Â
Hypersensitivity Â
Caution:Â Â
Pain in abdomen Â
Thrombocytopenia Â
Pregnancy Warnings:Â
Pregnancy category: N/AÂ
Lactation: Excretion of the drug into the human breast milk is unknownÂ
Pregnancy categories:Â
Pharmacology:Â Â
Bosutinib is an anticancer drug which belongs to the sub-class of Tyrosine Kinase inhibitors used to treat blood cancer. Â
Pharmacodynamics:Â Â
The pharmacodynamic properties of bosutinib are not fully known. Â
Pharmacokinetics:Â Â
Limited information is available on ADME. Â
Administration:Â Â
The drug is administered orally as oral dosage form. Â
Patient Information Leaflet  Â
Generic Name: bosutinib Â
Why do we use bosutinib? Â
Bosutinib is used to treat chronic myeloid leukemia, a type of blood cancer. Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
